The Japan Times - Canadian fund drops bid for Spanish pharma firm Grifols

EUR -
AED 4.029736
AFN 70.765955
ALL 89.669208
AMD 395.464201
ANG 1.964561
AOA 1007.296347
ARS 1720.667637
AUD 1.656015
AWG 1.977835
AZN 1.866107
BAM 1.955129
BBD 2.206342
BDT 136.253212
BGN 1.945982
BHD 0.413358
BIF 3299.46699
BMD 1.097273
BND 1.413215
BOB 12.789608
BRL 6.528224
BSD 1.095424
BTN 101.462159
BWP 15.618637
BYN 3.288671
BYR 21506.554825
BZD 2.203143
CAD 1.573435
CDF 2501.783104
CHF 0.922196
CLF 0.028442
CLP 1116.636556
CNY 7.327317
CNH 7.324019
COP 3761.108466
CRC 490.331624
CUC 1.097273
CUP 26.290972
CVE 110.227149
CZK 24.468918
DJF 195.073014
DKK 7.477813
DOP 66.087306
DZD 149.3917
EGP 58.610874
ERN 16.459098
ETB 179.798059
FJD 2.514456
FKP 0.838778
GBP 0.838894
GEL 2.854808
GGP 0.838778
GHS 12.898571
GIP 0.838778
GMD 81.198825
GNF 9711.665093
GTQ 8.373125
GYD 229.181301
HKD 8.60147
HNL 29.444889
HRK 7.496532
HTG 143.650672
HUF 373.311544
IDR 20072.363882
ILS 3.666045
IMP 0.838778
INR 101.695829
IQD 1660.729719
IRR 2125818.156093
ISK 137.279715
JEP 0.838778
JMD 173.530411
JOD 0.777935
JPY 173.978153
KES 142.46108
KGS 95.956143
KHR 4469.465222
KMF 492.675566
KPW 987.546269
KRW 1476.825505
KWD 0.342108
KYD 0.912887
KZT 499.698408
LAK 24694.520103
LBP 98101.31281
LKR 364.304901
LRD 183.486992
LSL 19.148924
LTL 3.239962
LVL 0.66373
LYD 7.087566
MAD 10.954738
MDL 20.079105
MGA 4964.295302
MKD 61.53387
MMK 2304.581267
MNT 3959.267951
MOP 8.844163
MRU 44.651667
MUR 51.330153
MVR 16.893838
MWK 1899.547711
MXN 20.963386
MYR 4.513099
MZN 70.123182
NAD 19.148924
NGN 1486.805408
NIO 40.316156
NOK 10.713441
NPR 162.339254
NZD 2.001167
OMR 0.418806
PAB 1.095424
PEN 3.760309
PGK 4.931307
PHP 70.245276
PKR 302.809418
PLN 4.458633
PYG 6907.627977
QAR 4.004325
RON 5.352275
RSD 117.589621
RUB 89.4029
RWF 1618.344274
SAR 4.116757
SBD 8.914262
SCR 15.355208
SDG 660.008163
SEK 11.143117
SGD 1.414826
SHP 0.838605
SLE 25.072492
SLL 23009.2745
SOS 626.085008
SRD 40.997965
STD 22711.339965
STN 24.49159
SVC 9.584709
SYP 14266.746586
SZL 19.144426
THB 37.356633
TJS 10.072641
TMT 3.840456
TND 3.318061
TOP 2.641971
TRY 55.454867
TTD 7.435447
TWD 36.176657
TZS 2922.096576
UAH 49.196806
UGX 4628.410642
USD 1.097273
UYU 44.544704
UZS 13114.496589
VES 1006.87737
VND 28311.294608
VUV 132.579886
WST 3.097911
XAF 655.957
XAG 0.026772
XAU 0.000311300841
XCD 2.965436
XCG 1.974322
XDR 0.775829
XOF 655.957
XPF 119.331742
YER 259.617863
ZAR 19.211883
ZMK 9876.777771
ZMW 22.555255
ZWL 353.321524
SSP 6337.566665
MXV 2.349931
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

Canadian fund drops bid for Spanish pharma firm Grifols
Canadian fund drops bid for Spanish pharma firm Grifols / Photo: Josep LAGO - AFP

Canadian fund drops bid for Spanish pharma firm Grifols

Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following disagreement over its valuation.

Text size:

Brookfield and the Grifols family, which owns about a third of the Barcelona-based company that makes medicine derived from blood plasma, have since July been in talks to take it private.

Earlier this month Brookfield made a 6.45-billion-euro bid for Grifols, offering a tentative non-binding price of 10.50 euros ($11) per share.

Grifols swiftly rejected the bid, saying it "significantly underestimated the fundamental prospects and long-term potential" of the company.

In a statement sent to Spanish stock market regulator CNMV, Brookfield said it was "not in a position to continue with a potential offer" for Grifols.

Grifols said its board agreed that "it is not feasible that the transaction goes ahead" and remains focused on "improving the company's long-term value".

Its share price plunged in January after US hedge fund Gotham City released a research note accusing the company of "manipulating" its reported debt and operational results to "artificially reduce" its debt ratio, and therefore its financing costs.

Grifols has repeatedly denied the allegations.

Gotham City is a prominent "short-seller" hedge fund that borrows stock in a company and sells it, hoping to buy it back cheaper to return it to the lender and pocket the difference.

Grifols traces its history back to 1909, first as a blood analysis and transfusion laboratory before specialising in products derived from blood plasma.

It is present in more than 30 countries including Australia, the United States and Japan. It posted revenue of 6.6 billion euros in 2023, a 10.9 percent increase over the previous year.

K.Tanaka--JT